Alternating Osimertinib and Gefitinib as Second-Line Treatment for EGFR-Mutated NSCLC Harbouring a T790M Resistance Mutation (OSCILLATE)

被引：0
|
作者：
Solomon, B. [1 ]
Mersiades, A. [2 ]
Brown, C. [2 ]
Dawson, S. [1 ]
Wong, S. [1 ]
Tan, L. [3 ]
Yip, S. [2 ]
Cheung, Y. [2 ]
Jurkovic, H. [2 ]
Walker, M. [2 ]
Kao, S. [4 ]
Lee, C. K. [5 ]
Newnham, G. [6 ]
O'Byrne, K. [7 ]
Parakh, S. [8 ]
Jasas, K. [9 ]
Bray, V. [10 ]
Stockler, M. [2 ]
John, T. [3 ]
Pavlakis, N. [11 ]
机构：
[1] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic, Australia
[2] Univ Sydney, Nhmrc Clin Trials Ctr, Sydney, NSW, Australia
[3] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[4] Chris OBrien Lifehouse, Dept Med Oncol, Sydney, NSW, Australia
[5] St George Hosp, Dept Med Oncol, Sydney, ACT, Australia
[6] St Vincents Hosp, Dept Med Oncol, Melbourne, Vic, Australia
[7] Princess Alexandra Hosp, Dept Med Oncol, Brisbane, Qld, Australia
[8] Austin Hosp, Dept Med Oncol, Melbourne, Vic, Australia
[9] Sir Charles Gairdner Hosp, Dept Med Oncol, Perth, WA, Australia
[10] Liverpool Hosp, Dept Med Oncol, Sydney, NSW, Australia
[11] Royal North Shore Hosp, Dept Med Oncol, Sydney, NSW, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
EGFR-mutated NSCLC; T790M resistance mutation; osimertinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.64
引用
收藏
页码：S615 / S616
页数：2
相关论文
共 50 条
  • [1] OSCILLATE - Phase 2 Trial of Alternating Osimertinib with Gefitinib in Patients with EGFR-T790M Mutation Positive Advanced NSCLC
    Solomon, B.
    Kok, P.
    Livingstone, A.
    Yip, S.
    Brown, C.
    Dawson, S.
    Wong, S.
    Pavlakis, N.
    Stockler, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2143 - S2143
  • [2] Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
    Kuiper, J. L.
    Heideman, D. A. M.
    Thunnissen, E.
    Paul, M. A.
    van Wijk, A. W.
    Postmus, P. E.
    Smit, E. F.
    LUNG CANCER, 2014, 85 (01) : 19 - 24
  • [3] Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid
    Theoleyre, Sandrine
    Masson, Ingrid
    Herbreteau, Guillaume
    Vallee, Audrey
    Senellart, Helene
    Denis, Marc G.
    LUNG CANCER, 2017, 114 : 111 - 112
  • [4] Successful treatment with osimertinib for leptomeningeal carcinomatosis from NSCLC with the EGFR T790M mutation
    Yoshimura, Naruo
    Takahashi, Hidenori
    Kurosawa, Emiko
    Tanaka, Akiko
    Ebina, Masahito
    Ohrui, Takashi
    ANNALS OF ONCOLOGY, 2019, 30 : 139 - 139
  • [5] Clinical implications of the T790M mutation in disease characteristics and treatment response in patients with EGFR-mutated NSCLC.
    Gaut, Daria
    Sim, Myung Shin
    Wolf, Brian R.
    Abarca, Phillip A.
    Carroll, James M.
    Goldman, Jonathan Wade
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
    Chih-Hsi Scott Kuo
    Chi-Hsien Huang
    Chien-Ying Liu
    Stelios Pavlidis
    Ho-Wen Ko
    Fu-Tsai Chung
    Tin-Yu Lin
    Chih-Liang Wang
    Yi-Ke Guo
    Cheng-Ta Yang
    Targeted Oncology, 2019, 14 : 433 - 440
  • [7] Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
    Kuo, Chih-Hsi Scott
    Huang, Chi-Hsien
    Liu, Chien-Ying
    Pavlidis, Stelios
    Ko, Ho-Wen
    Chung, Fu-Tsai
    Lin, Tin-Yu
    Wang, Chih-Liang
    Guo, Yi-Ke
    Yang, Cheng-Ta
    TARGETED ONCOLOGY, 2019, 14 (04) : 433 - 440
  • [8] Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status
    Lee, Jiyun
    Choi, Yoon La
    Han, Joungho
    Park, Sehhoon
    Jung, Hyun Ae
    Su, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (11) : 1758 - 1766
  • [9] Predictors of osimertinib response at second-line treatment in EGFR mutant non-small cell lung cancer patients with acquired T790M resistance mutation
    Dogan, I.
    Gurbuz, M.
    Paksoy, N.
    Khanmamadov, N.
    Vatansever, S.
    Saip, P.
    Demirkazik, A.
    Aydiner, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1351 - S1351
  • [10] Mechanisms of acquired resistance to osimertinib in advanced NSCLC with EGFR T790M mutation (LOGIK1607)
    Yamaguchi, Masafumi
    Osoegawa, Atsushi
    Nakamura, Tomomi
    Morinaga, Ryotaro
    Tanaka, Kentaro
    Kashiwabara, Kosuke
    Miura, Takashi
    Suetsugu, Takayuki
    Taguchi, Kenichi
    Nabeshima, Kazuki
    Kishimoto, Junji
    Sakai, Kazuko
    Nishio, Kazuto
    Sugio, Kenji
    CANCER SCIENCE, 2021, 112 : 567 - 567
12345